Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted Adjuvant Therapy in Nasopharyngeal Carcinoma
NCT07762976Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Started Aug 2026; status: recruiting.
02
Drugs
tislelizumabcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07762976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762976.